Cockayne Syndrome (CS) Cell Models for Research

Cockayne Syndrome (CS) is a rare autosomal recessive disorder with an estimated incidence of 2.5 per million live births in Western Europe (WHO, 2023). It is a progeroid syndrome characterized by growth failure, microcephaly, neurological degeneration, photosensitivity, and premature aging. The disease is progressive and often leads to death in the second or third decade of life. No curative treatment exists; management is supportive. The clinical heterogeneity and the lack of effective therapies underscore the need for robust research models.

CS serves as a paradigm for studying transcription-coupled repair (TCR), a subpathway of nucleotide excision repair (NER). The disease is caused by mutations in ERCC6 (CSB) and ERCC8 (CSA), which are involved in TCR. Research on CS has provided insights into the interplay between DNA repair, transcription, and aging. Public datasets, such as those in NCBI GEO, contain transcriptomic and epigenomic data from CS patient cells, facilitating mechanistic studies. Open questions include the role of CS proteins in mitochondrial function and oxidative stress, and the tissue-specific vulnerability.

Although CS is not a cancer predisposition syndrome, its molecular pathways are relevant to genomic stability. The primary defect is in transcription-coupled repair (TCR), which removes bulky DNA lesions from the transcribed strand of active genes. Key steps include:

• • Recognition of RNA polymerase II stalled at a lesion by CSB and CSA.
• • Recruitment of repair factors (XPA, XPG, TFIIH) to excise the lesion.
• • Resumption of transcription after repair.

Defects in this pathway lead to accumulation of DNA damage, transcriptional dysregulation, and apoptosis, particularly in neurons.

Data from ClinVar and NCBI Gene.

CSB and CSA interact with multiple signaling pathways:

• • Oxidative stress response: CSB is involved in base excision repair (BER) and regulates expression of antioxidant genes.
• • Mitochondrial function: CSB localizes to mitochondria and affects mitochondrial DNA repair.
• • Apoptosis: Defective TCR leads to p53 activation and apoptosis in neurons.
• • Autophagy: CSB deficiency impairs autophagy, contributing to protein aggregation.

Key nodes: p53, NRF2, mTOR, and SIRT1.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) are emerging as more physiologically relevant models, particularly for neurological studies.

• • Genetically engineered mouse models (GEMMs): ERCC6 knockout mice recapitulate many CS features, including growth retardation and neurological defects.
• • Induced models: UV-induced DNA damage in cell lines is used to study TCR.
• • Patient-derived xenografts (PDX): Not commonly used for CS due to its non-cancerous nature, but xenografts of CS fibroblasts can be used for in vivo studies.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise mutations in ERCC6 or ERCC8. These models are invaluable for studying genotype-phenotype correlations and for drug screening. Examples include:

• • ERCC6 knockout cell lines (e.g., in HEK293 or U2OS background) to study loss-of-function effects.
• • ERCC8 knockout cell lines to model CSA deficiency.
• • Knock-in lines with specific patient mutations (e.g., ERCC6 c.2281C>T) to study mutation-specific effects.

These sequence-verified models are commercially available from various sources, ensuring reproducibility and accelerating research.

Knockout and knock-in lines are used to validate the role of ERCC6 and ERCC8 in DNA repair and transcription. For example, ERCC6 knockout cells show hypersensitivity to UV irradiation and defective RNA synthesis recovery, confirming the gene's function. These lines can be complemented with wild-type or mutant constructs to assess rescue.

Isogenic pairs (wild-type vs. knockout) are used in high-throughput screens to identify compounds that modulate TCR or compensate for CS defects. For instance, screening for drugs that enhance cell survival after UV damage may identify therapeutic candidates. Additionally, these models can be used to test drugs that target oxidative stress pathways.

CRISPR synthetic lethality screens can identify genes that are essential in CS-deficient cells but not in wild-type cells. Such genes may serve as biomarkers or therapeutic targets. For example, inhibition of PARP1 has been shown to be synthetically lethal in CSB-deficient cells, providing a potential targeted therapy approach.